



Corrigendum

Corrigendum to “The relationship between atrial cardiopathy biomarkers and prognosis of patients with acute ischemic stroke after endovascular treatment” [Neurotherapeutics 21 (2) (2024) e00327]

Yixin Zhao ^{a,b,1}, Yuye Ning ^{c,1}, Lei Lei ^a, Qin Liu ^a, Mengmeng Li ^a, Xiangyu Lei ^a, Wanying Chen ^a, Yiting Hu ^d, Ting Xie ^e, Jiaxin Luan ^f, Haoyu Yang ^g, Guogang Luo ^{a,*}

^a Stroke Centre and Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, No. 277 Yanta West Road, Xi'an, 710061, China

^b Department of Neurology, Huashan Hospital, Fudan University, Shanghai, 200235, China

^c Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China

^d Pavlov First Saint Petersburg State Medical University, L'va Tolstogo Str. 6-8, Saint Petersburg, 197022, Russia

^e Stroke Centre and Department of Neurology, Hancheng People's Hospital of Shaanxi Province, Ziyun Dajie, and Huanghe Dajie, Hancheng, 715400, China

^f Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, No. 277 Yanta West Road, Xi'an, 710061, China

^g Pharmacy Department, The First Affiliated Hospital of Xi'an Jiaotong University, No. 277 Yanta West Road, Xi'an, 710061, China

The authors regret several errors in the original publication. Specifically, it has been identified that the number of patients in the atrial cardiopathy group should be 58, while the non-atrial cardiopathy group should encompass 29 individuals. These inaccuracies had a consequential impact on the presentation of data in Table 1 and Figure 2, as well as their corresponding descriptions. The correct sections are restated herein:

Abstract

Among these patients, 58 (66.7%) had atrial cardiopathy, while the remaining 29 (33.3%) did not. In the non-atrial cardiopathy group, 12 patients (41.4%) had poor functional outcomes (mRS>2), compared to 19 (32.8%) in the atrial cardiopathy group.

Results

Characteristics of included patients

The baseline characteristics of the atrial cardiopathy group (n = 58) and the non-atrial cardiopathy group (n = 29) were similar in terms of clinical severity or medical history.

Association between atrial cardiopathy and outcome

A poor outcome (mRS score of 3–6) was achieved by 19 (32.8%) patients with atrial cardiopathy and 12 (41.4%) patients with non-atrial cardiopathy.

DOI of original article: <https://doi.org/10.1016/j.neurot.2024.e00327>.

* Corresponding author.

E-mail address: lguogang@163.com (G. Luo).

¹ These authors contributed equally to this work.

<https://doi.org/10.1016/j.neurot.2024.e00361>

1878-7479/© 2024 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics. All rights reserved.

Table 1
Baseline characteristics of the patients.

	Total (n = 87)	Atrial cardiopathy group (n = 58)	Non-atrial cardiopathy group (n = 29)	P-value
Age, y, mean (SD)	60.93 ± 12.47	61.59 ± 11.80	59.62 ± 13.83	0.49
Gender, male, n (%)	72 (82.8)	45 (77.6)	27 (93.1)	0.08
Medical history, n (%)				
Hypertension	55 (63.2)	36 (62.1)	19 (65.5)	0.82
Diabetes mellitus	34 (39.1)	24 (41.4)	10 (34.5)	0.64
Coronary heart disease	11 (12.6)	7 (12.1)	4 (13.8)	1.00
Dyslipidemia	47 (54.0)	29 (50.0)	18 (62.1)	0.36
General status				
BMI, kg/m ²	24.61 ± 3.41	24.26 ± 3.68	25.36 ± 2.68	0.25
Admission SBP, mmHg	143.48 ± 23.20	148.18 ± 20.80	135.35 ± 25.24	0.02
Admission DBP, mmHg	82.64 ± 12.55	83.70 ± 12.31	80.77 ± 13.00	0.35
Admission NIHSS	10.11 ± 7.02	10.88 ± 7.40	8.59 ± 6.03	0.15
PR interval, M (Q)	153.84 ± 33.25	154.07 ± 37.64	153.38 ± 22.61	0.93
Laboratory examination				
WBC, cells/mL	10.55 ± 3.40	10.54 ± 3.42	10.56 ± 3.41	0.98
TC, mmol/L	4.10 ± 1.04	3.99 ± 0.90	4.31 ± 1.27	0.19
TG, mmol/L	1.28 ± 0.70	1.17 ± 0.64	1.50 ± 0.77	0.06
HDL, mmol/L	1.00 ± 0.23	1.01 ± 0.26	0.96 ± 0.16	0.08
LDL, mmol/L	2.37 ± 0.87	2.27 ± 0.83	2.56 ± 0.94	0.17
D-dimer, mg/L	2.34 ± 6.54	1.99 ± 3.79	3.08 ± 10.19	0.49
Hcy, μmol/L	27.90 ± 19.34	24.83 ± 14.93	30.36 ± 18.60	0.15
Echocardiography				
EF	65.48 ± 6.66	65.12 ± 7.27	66.21 ± 5.26	0.48
LVDD	47.57 ± 4.77	47.47 ± 4.72	47.75 ± 4.95	0.80
LVDS	30.31 ± 4.93	30.38 ± 5.36	30.18 ± 4.04	0.86
Endovascular treatment				
Internal carotid artery system	74 (85.1)	48 (82.8)	26 (89.7)	0.53
Vertebrobasilar system	13 (14.9)	10 (17.2)	3 (10.3)	0.53
IV rtPA, n (%)	30 (34.5)	20 (34.5)	10 (34.5)	1.00
Thrombectomy, n (%)	64 (73.6)	43 (74.1)	21 (72.4)	1.00
Stent implantation, n (%)	48 (55.2)	33 (56.9)	15 (51.7)	0.66
Balloon dilatation, n (%)	50 (57.5)	35 (60.3)	15 (51.7)	0.49
Contrast, ml	245.69 ± 78.80	249.22 ± 77.48	238.62 ± 82.28	0.56
TICI 2b/3, n (%)	66 (75.9)	47 (81.0)	19 (65.5)	0.11
The outcome, n (%)				
mRS>2	31 (35.6)	19 (32.8)	12 (41.4)	0.43
sICH	22 (25.3)	13 (22.4)	9 (31.0)	0.44
END	14 (16.1)	13 (22.4)	1 (3.4)	0.03
MCE	11 (12.6)	8 (13.8)	3 (10.3)	0.74
In-hospital death	2 (2.3)	0	2 (6.8)	0.31

Values are means (SD) or medians (IQR), or numbers (%).

Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; NIHSS, the National Institutes of Health Stroke Scale; WBC, white blood cells; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; Hcy, homocysteine; EF, ejection fraction; LVDD, left ventricular end diastolic diameter; LVDS, left ventricular end diastolic systolic diameter; IV, intravenous; rtPA, recombinant tissue plasminogen activator; TICI, thrombolysis in cerebral infarction; mRS, the modified Rankin scale; sICH, symptomatic intracranial hemorrhage; END, early neurological deterioration; MCE, malignant cerebral edema.

Additionally, a requisite correction has been applied to the count of individuals in the two-column headings of [Table 1](#), along with associated percentage errors. The labels of the two groups in [Figure 2](#) require interchange, and it is noteworthy that no significant difference in mRS

scores was observed between them. The complete and accurate versions of [Table 1](#) and [Figure 2](#) are restated in full herein.

The authors would like to apologise for any inconvenience caused.

